Clinical Research Directory
Browse clinical research sites, groups, and studies.
Colonoscopy and Antiplatelet Therapy Trial
Sponsor: Ochsner Health System
Summary
Patients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor \[clopidogrel, prasugrel, or ticagrelor\]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently, recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure. This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor. Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure. Periprocedural bleeding and bleeding after the procedure for iup to 30 days.
Official title: P2Y12 Inhibitor Versus Aspirin Monotherapy in Patients Undergoing Elective Screening and Surveillance Colonoscopy
Key Details
Gender
All
Age Range
45 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-10-01
Completion Date
2026-06-30
Last Updated
2024-09-25
Healthy Volunteers
No
Interventions
Aspirin
Participant will be on aspirin alone or P2Y12 inhibitor alone
P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
Participant will be taking either P2Y12 inhibitor at time of colonoscopy
Locations (1)
Ochsner Health
New Orleans, Louisiana, United States